Dalemans, R. Badaro, and S. G. Reed. 1999. Molecular characterization and
human T-cell responses to a member of a novel Mycobacterium tuberculosis
mtb39 gene family. Infect. Immun. 67:2941–2950.
Evans, J. T., C. W. Cluff, D. A. Johnson, M. J. Lacy, D. H. Persing, and J. R.
Baldridge. 2003. Enhancement of antigen-specific immunity via the TLR4
ligands MPL adjuvant and Ribi. 529. Expert Rev. Vaccines 2:219–229.
Fallo, A., E. De Matteo, M. V. Preciado, M. C. Cerqueiro, S. Escoms, P.
Chabay, and E. Lopez. 2005. Epstein-Barr virus associated with primary CNS
lymphoma and disseminated BCG infection in a child with AIDS. Int. J. In-fect. Dis. 9:96–103.
Fine, P. E. 2001. BCG: the challenge continues. Scand. J. Infect. Dis. 33:
243–245.
Ginsberg, A. M. 1998. The tuberculosis epidemic. Scientific challenges and
opportunities. Public Health Rep. 113:128–136.
Gupta, R. K., and G. R. Siber. 1995. Adjuvants for human vaccines—current
status, problems and future prospects. Vaccine 13:1263–1276.
Hagen, S. R., J. D. Thompson, D. S. Snyder, and K. R. Myers. 1997. Analysis
of a monophosphoryl lipid A immunostimulant preparation from Salmonella
minnesota R595 by high-performance liquid chromatography. J. Chromatogr. 767:53–61.
Hondalus, M. K., S. Bardarov, R. Russell, J. Chan, W. R. Jacobs, Jr., and
B. R. Bloom. 2000. Attenuation of and protection induced by a leucine
auxotroph of Mycobacterium tuberculosis. Infect. Immun. 68:2888–2898.
Kaufmann, S. H. 2000. Is the development of a new tuberculosis vaccine
possible? Nat. Med. 6:955–960.
Kaufmann, S. H. 2004. New issues in tuberculosis. Ann. Rheum. Dis.
63(Suppl. 2):ii50–ii56.
Kensil, C. R., U. Patel, M. Lennick, and D. Marciani. 1991. Separation and
characterization of saponins with adjuvant activity from Quillaja saponaria
Molina cortex. J. Immunol. 146:431–437.
Kensil, C. R., J. Y. Wu, and S. Soltysik. 1995. Structural and immunological
characterization of the vaccine adjuvant QS-21. Pharm. Biotechnol. 6:525–
541.
Lodes, M. J., D. C. Dillon, R. Mohamath, C. H. Day, D. R. Benson, L. D.
Reynolds, P. McNeill, D. P. Sampaio, Y. A. Skeiky, R. Badaro, D. H. Persing,
S. G. Reed, and R. L. Houghton. 2001. Serological expression cloning and
immunological evaluation of MTB48, a novel Mycobacterium tuberculosis
antigen. J. Clin. Microbiol. 39:2485–2493.
Lowrie, D. B., R. E. Tascon, V. L. Bonato, V. M. Lima, L. H. Faccioli, E.
Stavropoulos, M. J. Colston, R. G. Hewinson, K. Moelling, and C. L. Silva.
1999. Therapy of tuberculosis in mice by DNA vaccination. Nature 400:269–
271.
Lurie, M. B., P. Zappasodi, and C. Tickner. 1955. On the nature of genetic
resistance to tuberculosis in the light of the host-parasite relationships in
natively resistant and susceptible rabbits. Am. Rev. Tuberc. 72:297–329.
Marchand, M., C. J. Punt, S. Aamdal, B. Escudier, W. H. Kruit, U. Keilholz,
L. Hakansson, N. van Baren, Y. Humblet, P. Mulders, M. F. Avril, A. M.
Eggermont, C. Scheibenbogen, J. Uiters, J. Wanders, M. Delire, T. Boon,
and G. Stoter. 2003. Immunisation of metastatic cancer patients with
MAGE-3 protein combined with adjuvant SBAS-2: a clinical report. Eur. J.
Cancer 39:70–77.
Marsh, B. J., C. F. von Reyn, J. Edwards, M. A. Ristola, C. Bartholomew,
R. J. Brindle, C. F. Gilks, R. Waddell, A. N. Tosteson, R. Pelz, C. H. Sox, R.
Frothingham, and R. D. Arbeit. 1997. The risks and benefits of childhood
bacille Calmette-Guerin immunization among adults with AIDS. International MAC study groups. AIDS 11:669–672.
McCormack, S., A. Tilzey, A. Carmichael, F. Gotch, J. Kepple, A. Newberry,
G. Jones, S. Lister, S. Beddows, R. Cheingsong, A. Rees, A. Babiker, J.
Banatvala, C. Bruck, J. Darbyshire, D. Tyrrell, C. Van Hoecke, and J.
Weber. 2000. A phase I trial in HIV negative healthy volunteers evaluating
the effect of potent adjuvants on immunogenicity of a recombinant
gp120W61D derived from dual tropic R5X4 HIV-1ACH320. Vaccine 18:
1166–1177.
McMurray, D. M. 1994. Guinea pig model of tuberculosis, p. 135–147. In
B. R. Bloom (ed.), Tuberculosis: pathogenesis, protection and control. ASM
Press, Washington, D.C.
McShane, H., A. A. Pathan, C. R. Sander, S. M. Keating, S. C. Gilbert, K.
Huygen, H. A. Fletcher, and A. V. Hill. 2004. Recombinant modified vaccinia
virus Ankara expressing antigen 85A boosts BCG-primed and naturally
acquired antimycobacterial immunity in humans. Nat. Med. 10:1240–1244.
Mollenkopf, H. J., L. Grode, J. Mattow, M. Stein, P. Mann, B. Knapp, J.
Ulmer, and S. H. Kaufmann. 2004. Application of mycobacterial proteomics
to vaccine design: improved protection by Mycobacterium bovis BCG primeRv3407 DNA boost vaccination against tuberculosis. Infect. Immun. 72:
6471–6479.
Olsen, A. W., A. Williams, L. M. Okkels, G. Hatch, and P. Andersen. 2004.
Protective effect of a tuberculosis subunit vaccine based on a fusion of
antigen 85B and ESAT-6 in the aerosol guinea pig model. Infect. Immun.
72:6148–6150.
Orme, I. M. 2001. The search for new vaccines against tuberculosis. J. Leukoc.
Biol. 70:1–10.
